Search Results - "amyloid"

Imaging amyloid now that we can see it, what does it all mean? /

Table of Contents: “…Contents: Amyloid imaging PET tracers -- Development and validation -- Amyloid imaging in dementia -- Amyloid imaging in mild cognitive impairment -- Amyloid imaging in cognitively normal elderly -- Consequences of being amyloid-positive.…”
Get full text
Series

Imaging amyloid now that we can see it, what does it all mean? /

Table of Contents: “…Contents: Amyloid imaging PET tracers -- Development and validation -- Amyloid imaging in dementia -- Amyloid imaging in mild cognitive impairment -- Amyloid imaging in cognitively normal elderly -- Consequences of being amyloid-positive.…”
Get full text
Series

Imaging amyloid now that we can see it, what does it all mean? /

Table of Contents: “…Contents: Amyloid imaging PET tracers -- Development and validation -- Amyloid imaging in dementia -- Amyloid imaging in mild cognitive impairment -- Amyloid imaging in cognitively normal elderly -- Consequences of being amyloid-positive.…”
Get full text
Series

Neuroimaging markers in AD trials

Table of Contents: “…Contents: Imaging in Alzheimer's Disease (AD) trials -- Increasing range of modalities to measure brain structure, function and molecular pathology of AD -- Early diagnosis, inclusion markers and measurement of progression -- MRI to measure atrophy -- PET to measure amyloid.…”
Get full text
Series

Neuroimaging markers in AD trials

Table of Contents: “…Contents: Imaging in Alzheimer's Disease (AD) trials -- Increasing range of modalities to measure brain structure, function and molecular pathology of AD -- Early diagnosis, inclusion markers and measurement of progression -- MRI to measure atrophy -- PET to measure amyloid.…”
Get full text
Series

Neuroimaging markers in AD trials

Table of Contents: “…Contents: Imaging in Alzheimer's Disease (AD) trials -- Increasing range of modalities to measure brain structure, function and molecular pathology of AD -- Early diagnosis, inclusion markers and measurement of progression -- MRI to measure atrophy -- PET to measure amyloid.…”
Get full text
Series

Molecular brain imaging (PET) in diseases with dementia

Table of Contents: “…Contents: Brain imaging with positron emission tomography (PET) for dementia diagnosis and research -- Cerebral glucose metabolism in mild cognitive impairment, Alzheimer's disease, dementia with Lewy bodies, frontotemporal dementia & depression -- Imaging of pathological markers (beta-amyloid and tau) in Alzheimer's disease -- Imaging of neurotransmitters and receptors, in the dopaminergic and cholinergic system -- Multiple systems profiling in dementia, Parkinson's and related motor disorders.…”
Get full text
Series (Periodic reports)
Series (Neurodegenerative diseases)

Molecular brain imaging (PET) in diseases with dementia

Table of Contents: “…Contents: Brain imaging with positron emission tomography (PET) for dementia diagnosis and research -- Cerebral glucose metabolism in mild cognitive impairment, Alzheimer's disease, dementia with Lewy bodies, frontotemporal dementia & depression -- Imaging of pathological markers (beta-amyloid and tau) in Alzheimer's disease -- Imaging of neurotransmitters and receptors, in the dopaminergic and cholinergic system -- Multiple systems profiling in dementia, Parkinson's and related motor disorders.…”
Get full text
Series (Periodic reports)
Series (Neurodegenerative diseases)